The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndrome

Zhi-xin Yu1, Mu-sen Ji1, Jun Yan1, Yan Cai1, Jing Liu1, Hong-feng Yang1, Yong Li1, Zhao-chen Jin1* and Jin-xu Zheng2*

Abstract

Introduction: Recent studies have revealed that lung inflammation mediated by CD4+ T cells may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The imbalance between CD4+CD25+Foxp3+ regulatory T (Treg) cells and T helper (Th)17 cells has been found in a number of different inflammation and autoimmune diseases, while the role of the Th17/Treg balance in ARDS remains largely unknown. The aim of this study was to investigate the Th17/Treg pattern and its impact on disease severity and outcomes in patients with ARDS.

Methods: This prospective, observational study enrolled 79 patients who fulfilled the Berlin definition of ARDS and 26 age- and sex-matched healthy controls. Circulation Th17 and Treg cell frequencies were analyzed by flow cytometry, and the expressions of Th17- and Treg-related cytokines in serum were measured by enzyme-linked immunosorbent assay (ELISA). Acute Physiologic and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, and the Lung Injury Score were also calculated at enrollment.

Results: Within 24 hours after the onset of ARDS, the changes of peripheral circulating Th17 and Treg cell frequencies gradually increased from mild to severe ARDS. Th17/Treg ratio was positively correlated with APACHE II score, SOFA score, and Lung Injury Score, while negatively correlated with PaO2/FiO2. The areas under the receiver operating characteristic (AUC) curves of Th17/Treg ratio for predicting 28-day mortality in ARDS patients was higher than that of APACHE II score, SOFA score, Lung injury score, as well as PaO2/FiO2. Using a Th17/Treg ratio cutoff value of >0.79 to determine 28-day mortality, the sensitivity was 87.5% with 68.1% specificity. Multivariate logistic regression showed Th17/Treg ratio >0.79 (odds ratio = 8.68, P = 0.002) was the independent predictor for 28-day mortality in patients with ARDS. Finally, cumulative survival rates at 28-day follow-up also differed significantly between patients with Th17/Treg ratio >0.79 and ≤0.79 (P <0.001).

Conclusions: The Th17/Treg imbalance favoring a Th17 shift represents a potential therapeutic target to alleviate lung injury and a novel risk indicator in patients with early ARDS.

Introduction

Acute respiratory distress syndrome (ARDS) is a life-threatening clinical syndrome of rapid-onset pulmonary failure with high morbidity and mortality in critically ill patients [1,2]. Despite decades of intense research, the pathogenesis leading to this devastating disease remains poorly defined. However, clinical and animal studies have shown that activation of multiple inflammatory cells and release of inflammatory mediators play an important role in the development and outcome of ARDS [1]. Among those cells, immune cells including neutrophils [3], macrophages [4] and dendritic cells [5] involved in this process have been studied extensively. Most recently, the involvement of lymphocytes, especially CD4+ T cells, in the pathogenesis of ARDS has become an active topic of research [6-12].

CD4+CD25+Foxp3+regulatory T (Treg) cells have an anti-inflammatory role mainly by contact-dependent suppression or releasing cytokines, IL-10 and transforming growth factor (TGF)-β1 on other immune cells, including CD4+ and CD8+ T cells, B cells, natural killer
(NK) cells and dendritic cells [13]. Numerous publications have revealed that reduced generation or deficient function of Treg cells, which is associated with disease severity and activity, has been found in patients with various inflammation and autoimmune diseases [13]. In mice and patients with acute lung injury (ALI), the alveolar recruitment of Treg cells, specifically mediated by leukotriene B4 (LTB4)-leukotriene B4 Receptor (BLT1) pathway [10], contribute to the resolution of lung inflammation [7], particularly in the resolution of ALI fibroproliferation [9]. However, data from a recent observational clinical study showed that an increased Treg cell ratio in bronchoalveolar lavage fluid (BALF) obtained from ARDS patients on admission is an independent risk factor for 30-day mortality [8]. Therefore, the precise role of Treg cells on ARDS and its resolution remains to be explored.

In contrast to Treg cells, a more recently discovered effector subset of CD4+ T cells, Th17 cells play a potent proinflammatory role in the immune system through producing the signature cytokines IL-17 and to a lesser extent other inflammatory mediators including IL-6, TNF-α, granulocyte-macrophage colonystimulating factor [13]. In addition to their effector function in defense against extracellular pathogens, Th helper (Th17) cells can promote many autoimmune inflammatory conditions including several lung diseases (asthma [14], tuberculosis [15], lung cancer [16], and chronic obstructive pulmonary disease [17]), unless they are efficiently controlled by regulatory cells [13]. Remarkably, Th17 development relies on the key cytokine TGF-β1, which is also linked to Treg cell development and function, indicating that Th17 and Treg not only exert opposite functions in the immune response but also share reciprocal development pathways. Moreover, under certain inflammatory environments, differentiated Treg cells have a tendency to be reprogrammed and converted into Th17 cells [13,18]. Thus, it is reasonable to hypothesize that the fine balance between Th17 and Treg is crucial for maintenance of immune homeostasis.

The imbalance of Th17/Treg has also been found in a number of different inflammation and autoimmune diseases [13]. Although the role of Th17 cells in the development and progress of ARDS is currently unclear, IL-17, the cytokine preferentially produced by Th17 cells, has been widely investigated in lung diseases including ARDS [19]. Furthermore, Th17 cells have been implicated in other lung diseases in animal experimentation and clinical studies [20]. In addition to Th17 cells found in the BALF fluid of patients with respiratory diseases, two studies have shown that losartan and alanylglutamine may protect mice from lipopolysaccharide-induced lung injury by suppressing Th17 immune responses and modulating the Th17/Treg balance in favor of Treg cells, respectively [5,12]. Therefore, we hypothesize that the imbalance of Th17/Treg might exist and play a role in the pathogenesis of inflammation in ARDS. To test this hypothesis, we investigated the distribution of Th17 cells in relation to Treg cells in ARDS patients, and evaluated how the imbalance of Th17/Treg and their related cytokines correlate with the disease severity.

**Materials and methods**

**Subjects and protocol**

This prospective, observational study was conducted in the 30-bed, level-3 multi-disciplinary, adult ICU of the Affiliated People’s Hospital, Jiangsu University. Between June 2012 and January 2014, consecutive patients admitted to our ICU were considered eligible if they met the Berlin definition of ARDS [2]. Patients were classified according to the arterial partial pressure of oxygen/inspired oxygen fraction (PaO₂/FiO₂) ratio as mild (200 mmHg < PaO₂/FiO₂ ≤ 300 mmHg, n = 24), moderate (100 mmHg < PaO₂/FiO₂ ≤ 200 mmHg, n = 28), and severe (PaO₂/FiO₂ ≤ 100 mmHg, n = 27). The exclusion criteria were as follows: age <18 years, known history of cancer, end-stage liver or renal disease, and chronic immune-mediated disorders. At the time of sample collection, none of the patients had received any corticosteroids, or other non-steroid anti-inflammatory drugs. In addition, we also excluded the patients who died within 24 h of receiving a diagnosis of ARDS.

Finally, after excluding 12 patients who failed to meet the inclusion criteria and 7 patients who were lost to follow up, 79 patients were enrolled and were also categorized as survivors (n = 47) and non-survivors (n = 32) according to clinical outcome within 28 days of follow up. Twenty-six age- and sex-matched healthy volunteers without a history of any chronic disease served as controls. This study was approved by the Ethics Committee of the Affiliated People’s Hospital, Jiangsu University. Informed consent from all of the subjects or their relatives was obtained before enrollment.

**Data collection and outcome**

After enrollment, demographics and baseline characteristics such as age, sex, body mass index (BMI), risk factors for ARDS, severity of illness at ICU admission (acute physiologic and chronic health evaluation (APACHE) II score) [21], sequential organ failure assessment (SOFA) score [22], and the lung injury score [23] were also calculated after ICU admission. All patients were followed up for 28 days. The main outcomes were mortality at discharge from ICU and from hospital at 28 days.
Blood sampling and measurements
Within 24 h after diagnosis of ARDS, peripheral whole blood samples were collected in tubes containing heparin or ethylene diamine tetraacetate acid (EDTA), and serum was obtained after centrifugation and stored at −80°C until used. White blood cell count, C-reactive protein (CPR) and procalcitonin (PCT) were immediately measured in the clinical chemistry laboratory of the Affiliated People’s Hospital. The serum levels of TGF-β1, IL-6, IL-10, and IL-17 (all from R&D Systems, Minneapolis, MN) were determined by enzyme-linked immunosorbent assay (ELISA), following the manufacturer’s instructions.

Flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) were freshly isolated by Ficoll density gradient centrifugation (Pharmacia, Uppsala, Sweden). The isolated PBMCs were washed twice with PBS and resuspended at 1 × 10⁶ cells/mL in complete culture medium (RPMI 1640 supplemented with 1% penicillin/streptomycin, 2 mM l-glutamine, and 10% heat-inactivated fetal bovine serum; Gibco BRL, Gaithersburg, MD, USA).

For Th17 cells analysis, IL-17-producing CD3+ lymphocytes were detected as described previously [24]. PBMCs were stimulated for 4 h with 2 μg/mL leukocyte activation cocktail (BD Pharmingen™, USA) at 37°C and 5% CO₂. Upon harvest, cells were then washed twice using PBS, and surface-stained with APC-conjugated anti-CD8 (BD Pharmingen™, USA) and PerCP-conjugated anti-CD3 (BD Pharmingen™, USA) for 20 minutes at room temperature in the dark. Following surface staining, cells were incubated with PE-conjugated anti-IL-17A (BD Pharmingen™, USA) after fixation and permeabilization using the IntraPrep Permeabilization Reagent (Beckman Coulter Inc., France).

For the analysis of Treg cells, a human regulatory T-cell staining kit (BD Pharmingen™, USA) was used to measure CD4+ CD25 + Foxp3+ cells as Treg cells according to the manufacturer’s protocol. Briefly, PBMCs was incubated with a cocktail of fluorescein isothiocyanate-conjugated anti-CD4 and APC-conjugated anti-CD25 for 30 minutes at 4°C. After fixation and permeabilization, the cells were blocked by normal rat serum and stained using PE-conjugated anti-Foxp3 for 45 minutes at 4°C.

The flow cytometry analyses were performed on a FACSCalibur flow cytometer (BD biosciences, San Jose, CA, USA) equipped with CellQuest software (BD biosciences). Isotype controls were conducted to ensure antibody specificity.

Statistical analysis
All analyses were done using SPSS, version 20.0 (IBM Corp., Armonk, NY, USA) and MedCalc version 11.0 (MedCalc Software, Inc, Mariakerke, Belgium). Continuous variables were reported as mean ± SD or as median (IQR) after testing their normal distribution using the Kolmogorov-Smirnov test.

For two-group comparisons, the independent samples t-test was used for normally distributed data, and the Mann-Whitney test was used for non-normally distributed data. For the comparison of multi-group, one-way analysis of variance and the Kruskal-Wallis test was used to analyze normally and non-normally distributed data, respectively, and P-values were adjusted with the Bonferroni correction for multiple comparisons. Categorical data are summarized using number (percentage), and were compared using the chi-square or Fisher’s exact test. Spearman’s rank correlation was applied to determine the correlation between variables.

The area under the receiver operating characteristic (ROC) curve was calculated to evaluate the diagnostic and prognostic value of the tested parameters. The cutoff points were calculated by acquiring the best Youden index (sensitivity + specificity − 1). Kaplan-Meier plots and the log-rank test were used to compare survival in several groups. To determine the independent predictors of 28-day mortality, binary logistic regression analysis was performed as stepwise regression (entering a variable if P was <0.05, removing a variable if P was >0.10) for variables with a P-value of <0.05. Results were expressed as the odds ratio (OR), P-value and 95% CI.

All tests were two-tailed, and a value of P <0.05 was considered statistically significant. In addition, P <0.008 (after Bonferroni correction) was used for multiple comparisons.

Results
Baseline characteristics and patient outcome
Between June 2012 and January 2014, a total of 79 patients who fulfilled the Berlin definition of ARDS and 26 healthy volunteers were included in this study. Tables 1 and 2 show the characteristics at enrollment and outcomes of the study population. No significant differences were found in age, gender and body mass index (BMI) among the four groups (mild, moderate, severe ARDS, and control groups). Pneumonia, sepsis and trauma were the most common etiology of ARDS. As shown in Tables 1 and 2, severity of critical illness on the day of enrollment, measured by the APACHE II score (P <0.001), SOFA score (P <0.001), lung injury score (P <0.001) and PaO₂/FiO₂ (P <0.001), worsened from mild to severe ARDS. The 28-day mortality was 40.5% (32/79) in patients with ARDS. Compared with survivors, non-survivors had significantly higher APACHE II and SOFA scores. In addition, survivors had higher PaO₂/FiO₂ and lower lung injury score than non-survivors.
Table 1 Baseline characteristics of the population enrolled in the study

| Variables                      | Control | Acute respiratory distress syndrome | P-value |
|--------------------------------|---------|-------------------------------------|---------|
|                                |         | Total | Mild | Moderate | Severe |         |
| Number                         | 26      | 79   | 24   | 28       | 27     | 0.714   |
| Age, years                     | 54.00 ± 13.77 | 55.03 ± 14.42 | 55.17 ± 15.45 | 53.36 ± 13.34 | 57.63 ± 15.57 | 0.971   |
| Gender, male/female, n         | 14/12   | 44/35 | 13/11 | 15/13    | 16/11  | 0.150   |
| BMI, kg/m²                     | 22.44 ± 3.53 | 24.03 ± 4.13 | 24.72 ± 4.98 | 24.67 ± 3.84 | 24.26 ± 3.93 | 0.010   |
| Cause of ARDS                  |         |       |      |          |        |         |
| Pneumonia                      | 25      | 6     | 9    | 10       |        |         |
| Non-pulmonary sepsis           | 19      | 4     | 8    | 7        |        |         |
| Trauma                         | 23      | 9     | 6    | 8        |        |         |
| Aspiration                     | 5       | 2     | 2    | 1        |        |         |
| Multiple transfusions          | 4       | 2     | 2    |          |        |         |
| Others                         | 3       | 1     | 1    | 1        |        |         |
| APACHE II score                | 22 (20 to 26) | 20 (18 to 22) | 23 (21 to 26)* | 25 (22 to 27)* |        | <0.001  |
| SOFA score                     | 11.0 (10.0 to 13.0) | 9.5 (7.0 to 11.8) | 11.0 (10.0 to 13.0)* | 12.0 (11.0 to 13.0)* |        | <0.001  |
| Lung injury score              | 2.3 (2.1 to 2.8) | 2.0 (1.9 to 2.1) | 2.3 (2.1 to 2.5)* | 2.9 (2.7 to 3.2)* |        | <0.001  |
| PaO₂/FiO₂ (mmHg)               | 138 (76 to 222) | 258 (223 to 273) | 139 (120 to 158)* | 67 (59 to 79)* |        | <0.001  |
| CRP, mg/L                      | 4.97 (3.83 to 6.12) | 135.84 (116.83 to 156.79) | 116.69 (104.17 to 133.33) | 130.97 (123.40 to 154.45) | 156.85 (143.59 to 185.36)* | <0.001 |
| PCT, ng/mL                     | 0.04 (0.02 to 0.06) | 1.56 (1.24 to 1.83) | 1.24 (1.05 to 1.36) | 1.47 (1.27 to 1.66) | 2.04 (1.62 to 2.61)* | <0.001 |
| Leukocytes, 10⁹/L              | 6.85 (5.6 to 8.2) | 12.9 (11.2 to 14.8) | 11.8 (10.5 to 12.8) | 12.4 (10.7 to 13.7) | 15.3 (13.6 to 17.6)* | <0.001 |
| Monocytes, 10⁹/L               | 0.58 (0.46 to 0.69) | 1.05 (0.92 to 1.23) | 0.95 (0.84 to 1.13) | 1.04 (0.88 to 1.23) | 1.12 (1.04 to 1.16)* | <0.001 |
| Lymphocytes, 10⁹/L             | 3.09 (2.80 to 3.52) | 5.35 (4.25 to 6.47) | 4.24 (3.93 to 4.96) | 5.24 (4.19 to 6.06)* | 6.72 (5.69 to 7.45)* | <0.001 |
| Th17 cells, % of CD4⁺          | 0.71 (0.59 to 0.94) | 4.27 (3.67 to 6.02) | 3.54 (3.17 to 3.94) | 4.16 (3.96 to 4.54)* | 6.42 (5.96 to 6.91)* | <0.001 |
| Treg cells, % of CD4⁺          | 3.11 (2.70 to 3.44) | 5.37 (4.98 to 6.07) | 4.82 (4.50 to 5.18) | 5.46 (5.25 to 5.81)* | 6.18 (5.82 to 6.57)* | <0.001 |
| Th17/Treg ratio                | 0.25 ± 0.09 | 0.86 ± 0.20 | 0.74 ± 0.12 | 0.77 ± 0.10 | 1.01 ± 0.18* | <0.001 |
| IL-6, pg/mL                    | 11.70 ± 1.31 | 758.33 ± 70.03 | 721.53 ± 54.43 | 763.62 ± 76.96* | 785.56 ± 62.36* | <0.001 |
| IL-17, pg/mL                   | 20.27 ± 4.12 | 199.59 ± 68.12 | 139.42 ± 25.51 | 204.75 ± 37.64* | 247.72 ± 78.08* | <0.001 |
| IL-10, pg/mL                   | 123.04 ± 20.53 | 131.19 ± 19.94 | 137.8 ± 19.17 | 132.49 ± 20.14 | 124.17 ± 18.87 | 0.029 |
| TGF-β, pg/mL                   | 193.48 ± 46.48 | 209.92 ± 51.00 | 219.30 ± 61.84 | 200.30 ± 41.77 | 211.55 ± 49.25 | 0.264 |
| 28-day mortality, n, %         | 32 (40.5%) | 7 (29.1%) | 12 (42.8%) | 13 (48.15%) |        |         |

Quantitative data with a normal distribution are presented as mean ± SD. Quantitative data with a non-normal distribution are presented as median (IQR). Qualitative data are presented as number (%). *P-value for the four groups (mild, moderate, severe ARDS, and control groups); **P < 0.01 versus mild ARDS; ***P < 0.01 versus moderate ARDS. BMI, body mass index; APACHE, acute physiologic and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C-reactive protein; PCT, procalcitonin.
Alteration of inflammatory biomarkers, circulating Th17 and Treg cells and their associated cytokines in ARDS patients

The changes in inflammatory biomarkers, Th17 and Treg cell frequencies and their associated cytokine levels in each group are shown in Tables 1 and 2. Compared to the healthy control group, the levels of CRP and PCT, and the counts of leukocytes, monocytes, and lymphocytes were markedly elevated in ARDS patients ($P < 0.001$) (Table 1). PCT levels and leukocyte counts were higher in patients with severe ARDS than in patients with mild or moderate ARDS, and patients with severe ARDS also had higher CPR levels and monocytes count as compared to patients with mild ARDS ($P < 0.01$) (Table 1). Interestingly, the lymphocyte count increased as the severity of ARDS increased from mild to severe ($P < 0.01$) (Table 1).

Non-survivors had higher PCT levels and lymphocyte counts than did survivors, but the CRP levels and leukocyte and monocyte counts were similar in the two groups (Table 2).

As shown in Table 1, the frequencies of Th17 and Treg cells were evidently increased in the peripheral blood of ARDS patients than those in the control group ($P < 0.001$). Moreover, the changes in Th17 and Treg cell frequencies progressively increased with ARDS severity from mild to moderate and severe ARDS ($P < 0.01$). However, although the frequencies of Th17 cells in non-survivors were higher as compared to those in survivors, there was no significant difference between two groups in frequencies of Treg cells (Table 2). Given the changes in these two types of immune cells, we used the Th17/Treg ratio to describe their relationship to further investigate their functions and differentiation. The Th17/Treg ratio was significantly higher in patients with ARDS when compared with the control group ($P < 0.001$, Table 1). Furthermore, patients with severe ARDS had a higher Th17/Treg ratio than patients with mild and moderate ARDS ($P < 0.01$) (Table 1). In non-survivors, a highly significant Th17/Treg ratio was also found in favor of a proinflammatory Th17-response ($P < 0.001$) (Table 2).

Th17-related cytokines (IL-6, IL-17) and Treg-related cytokines (IL-10, TGF-$\beta$) were detected by means of ELISA (Tables 1 and 2). IL-6 and IL-17 were significantly higher compared with those in the control group ($P < 0.001$) (Table 1), and both these cytokines were associated with the severity or progression of ARDS, as non-survivors had significantly higher IL-6 and IL-17 levels ($P < 0.001$, $P = 0.003$, respectively) (Table 2). While IL-10 levels was increased in ARDS patients

| Variables                      | Non-survivors (n = 32) | Survivors (n = 47) | $P$-value |
|-------------------------------|------------------------|--------------------|-----------|
| Age, years                    | 53.38 ± 13.80          | 56.72 ± 15.27      | 0.323     |
| Gender, male/female, n        | 17/15                  | 26/21              | 0.848     |
| BMI, kg/m$^2$                 | 24.34 ± 4.12           | 24.69 ± 4.29       | 0.716     |
| APACHE II score               | 26 (22 to 27)          | 21 (19 to 23)      | <0.001    |
| SOFA score                    | 12 (11 to 13)          | 10 (9 to 12)       | <0.001    |
| Lung injury score             | 2.6 (2.2 to 3.1)       | 2.1 (2.0 to 2.7)   | 0.002     |
| PaO$_2$/FiO$_2$, mmHg         | 111 (67 to 183)        | 157 (84 to 231)    | 0.037     |
| CRP, mg/L                     | 138.59 (123.40 to 165.47) | 135.64 (116.53 to 156.76) | 0.413     |
| PCT, ng/mL                    | 1.64 (1.33 to 2.05)    | 1.38 (1.07 to 1.67) | 0.031     |
| Leukocytes, 10$^9$/L          | 13.2 (11.5 to 15.8)    | 12.7 (10.8 to 14.5) | 0.507     |
| Monocytes, 10$^9$/L           | 1.07 (0.99 to 1.28)    | 1.04 (0.88 to 1.18) | 0.124     |
| Lymphocytes, 10$^9$/L         | 5.76 (4.80 to 6.61)    | 5.10 (4.16 to 6.21) | 0.044     |
| Th17 cells, % of CD4$^+$      | 4.84 (4.25 to 6.76)    | 4.01 (3.56 to 5.34) | <0.001    |
| Treg cells, % of CD4$^+$      | 5.33 (4.98 to 5.94)    | 5.46 (4.98 to 6.12) | 0.583     |
| Th17/Treg ratio               | 0.98 ± 0.20            | 0.78 ± 0.15        | <0.001    |
| IL-6, pg/mL                   | 790.68 ± 66.95         | 736.30 ± 63.80     | <0.001    |
| IL-17, pg/mL                  | 229.09 ± 77.18         | 179.50 ± 53.25     | 0.003     |
| IL-10, pg/mL                  | 128.48 ± 21.87         | 133.04 ± 18.53     | 0.321     |
| TGF-$\beta$, pg/mL           | 216.81 ± 55.44         | 205.23 ± 47.80     | 0.325     |

Quantitative data with a normal distribution are presented as mean ± SD. Quantitative data with a non-normal distribution are presented as median (IQR). BMI, body mass index; APACHE, acute physiologic and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C-reactive protein; PCT, procalcitonin.
when compared to those in the control group \((P = 0.029)\) (Table 1), there was no significant difference in the TGF-β1 levels among all groups \((P = 0.264)\) (Table 1). In addition, levels of both IL-10 and TGF-β1 were similar between survivors and non-survivors \((P = 0.321, P = 0.325, \text{respectively})\) (Table 2).

**Correlation of Th17/Treg ratio with disease severity and outcome**

Spearman correlation analysis of Th17/Treg ratio with APACHE II score, SOFA score, lung injury score, and PaO\(_2\)/FiO\(_2\) in ARDS patients are displayed in Figure 1. For all patients with ARDS, the significantly positive and moderate correlations were found between Th17/Treg ratio and APACHE II score \((r = 0.499, P < 0.001)\), SOFA score \((r = 0.363, P = 0.001)\), Lung injury score \((r = 0.699, P < 0.001)\), respectively. Furthermore, we noticed a negative and moderate correlation between the Th17/Treg ratio and PaO\(_2\)/FiO\(_2\) \((r = −0.670, P < 0.001)\).

The ROC curves for Th17/Treg ratio, APACHE II score, SOFA score, lung injury score, PaO\(_2\)/FiO\(_2\) and Th17/Treg ratio in combination with APACHE II score for predicting 28-day mortality in ARDS patients are shown in Figure 2. The area under the ROC curve (AUC) of Th17/Treg ratio for predicting 28-day mortality in ARDS patients was 0.824 (95% CI 0.722 to 0.901), higher than that for the APACHE II score \((0.791, 95\% CI 0.684 \text{ to } 0.874)\), but this was not statistically significant \((P = 0.558)\). Compared to the Th17/Treg ratio, the AUC for the lung injury score \((0.704, 95\% CI 0.590 \text{ to } 0.801)\) was significantly lower \((P = 0.011)\); the AUC for the SOFA score was also lower \((0.749, 95\% CI 0.639 \text{ to } 0.840)\), but this difference did not reach statistical significance \((P = 0.257)\). Moreover, the AUC for PaO\(_2\)/FiO\(_2\) for 28-day mortality was 0.639 (95% CI 0.523 to 0.744) compared to the AUC for the Th17/Treg ratio, APACHE II score, SOFA score, and lung injury score \((P = 0.0001, 0.01, 0.132, \text{and } 0.063, \text{respectively})\). The AUC for the Th17/Treg ratio in combination with the APACHE II score was 0.872 (95% CI 0.790 to 0.954), which was significantly higher than that for the APACHE II score alone for predicting 28-day mortality \((P = 0.034)\), and there was no difference for the combination of the Th17/Treg ratio and APACHE II score compared with the Th17/Treg ratio alone \((P = 0.171)\).

Using a Th17/Treg ratio cutoff value of \(>0.79\) for predicting 28-day mortality in patients with ARDS, the sensitivity and specificity was 87.5% and 68.1%, respectively, and the positive and negative likelihood ratios were 2.74 and 0.18.

**Predictors for 28-day mortality in patients with ARDS**

Table 3 shows that the Th17/Treg ratio \((\text{OR} = 8.68, P = 0.002)\), APACHE II score \((\text{OR} = 1.32, P = 0.007)\), and
SOFa score (OR = 1.49, \( P = 0.030 \)) were the independent predictors of 28-day mortality in patients with ARDS. Moreover, ARDS patients with a Th17/Treg ratio >0.79 had higher 28-day mortality (\( P < 0.001 \), Figure 3).

**Discussion**

It is generally believed that inflammatory cells and their associated mediators are mandatory in the pathological process of ARDS. Over the past few decades, despite extensive studies on these cells and mediators in both humans and mice, the pathogenesis of ARDS remains poorly understood [1,3,4,25]. Recently, it has been suggested that T lymphocytes, especially CD4+ T cells, contribute to the progress of autoimmune and inflammation diseases, including ARDS [1,5-12]. In this study, we demonstrated that the Th17/Treg balance in the peripheral...
blood of patients with ARDS changed toward a Th17 response compared to the control group. Moreover, the circulating Th17/Treg ratio of non-survivors was significantly higher than that of survivors. The ratio of Th17/Treg cells was also closely related to the severity of illness and 28-day mortality in ARDS patients. Thus, the skewing of the Th17/Treg ratio may contribute to the pathogenesis of ARDS.

Prior studies have shown that Treg cells, as important regulators of immune response mainly though cell-to-cell contact and secretion of the inhibitory cytokines IL-10 and TGF-β, infiltrate the lung and may be involved in pathogenesis of ARDS. D’Alessio et al. showed for the first time that Treg cells accumulate in the BALF of mice and patients with ALI and contribute to the resolution of ALI by inducing TGF-β and neutrophil apoptosis [7]. They further showed that Treg cells reduce ALI fibroproliferation through control of fibrocyte recruitment to the lung after lipopolysaccharide-induced injury [9]. Moreover, Wang et al. demonstrated that the well-known proinflammatory LTB4-BLT1 pathway may contribute to the resolution of ALI by mediating the alveolar recruitment of Treg cells [10]. In addition to these studies that were mainly performed in mice with ALI, in a recent observational clinical study the researchers reported that an increased ratio of CD4+ CD25+ Foxp3+ Treg cells to all CD4+ cells in BALF obtained from ARDS patients on admission is an independent risk factor for 30-day mortality, although the ratio of Treg to all CD4+ cells in the blood was not associated with 30-day mortality and did not differ between patients with ARDS and controls [8]. However, in the current study, the Treg cell percentage in peripheral blood was significantly higher in patients with ARDS than in the control group. Furthermore, the changes in Treg cell frequencies progressively increased with ARDS severity from mild to moderate and severe ARDS. The frequency of Treg cells in survivors tended to be higher, although this trend did not reach statistical significance. The difference may be largely due to the different study groups. Adamzik et al. only studied ARDS cases caused by community-acquired pneumonia, whereas we recruited a mixed population including patients with pulmonary and extrapulmonary ARDS. Indeed, ARDS is a heterogeneous syndrome that can occur as a result of multiple insults and diseases. It is noteworthy that the differences between pulmonary and extrapulmonary ARDS may exist not only in morphology and respiratory physiology but also in response to therapeutic interventions, despite the fact that a common end state may be present [26].

As a more recently discovered effector subset of CD4+ T cells, Th17 cells play a key role in defense against extracellular pathogens, and promote many autoimmune inflammatory conditions [13]. Although the role of Th17 cells has been investigated in several lung diseases, such as asthma [14], tuberculosis [15], lung cancer [16], and chronic obstructive pulmonary disease [17], there are

| Variables               | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | Odds ratio (95% CI) | P-value               | Odds ratio (95% CI) | P-value               |
| APACHE II score, per point | 1.42 (1.19, 1.68)   | <0.001                | 1.32 (1.08, 1.62)   | 0.007                 |
| SOFA score, per point    | 1.62 (1.22, 2.15)   | 0.01                  | 1.49 (1.04, 2.15)   | 0.030                 |
| Lung injury score, >2.1 | 5.18 (1.70, 15.74)  | 0.004                 |                       |                       |
| PaO₂/FiO₂, per log₁₀ (mmHg) | 0.14 (0.02, 1.00) | 0.051                 |                       |                       |
| PCT, per log₁₀ (ng/mL)  | 2.38 (0.98, 5.78)   | 0.056                 |                       |                       |
| Lymphocytes, >5.24 x 10⁶/L | 2.97 (1.15, 7.64)  | 0.024                 |                       |                       |
| Th17 cells, >4.12% of CD4+ | 8.70 (2.84, 26.69) | <0.001                |                       |                       |
| IL-6, >794.63 pg/mL     | 5.53 (1.97, 15.48)  | 0.001                 |                       |                       |
| IL-17, >188.56 pg/mL    | 3.88 (1.49, 10.09)  | 0.005                 |                       |                       |
| Th17/Treg ratio, >0.79  | 14.93 (4.44, 50.28) | <0.001                | 8.68 (2.25, 33.54)   | 0.002                 |

APACHE, acute physiologic and chronic health evaluation; SOFA, sequential organ failure assessment; PCT, procalcitonin.

Figure 3 Kaplan-Meier survival curve for patients with ARDS using the cutoff value of Th17/Treg ratio based on receiver operating characteristic (ROC) analysis. Log-rank test (P <0.001).
few data about the peripheral frequency of Th17 cells in ARDS patients. In our study, we found that ARDS patients exhibited a significant increase in the frequency of Th17 cells and their signature cytokine, IL-17, compared to the control group. Moreover, a similar significant difference was observed between survivors and non-survivors. These results suggest a potential role for circulating Th17 cells to reflect the severity of lung injury.

Th17 cells and Treg cells not only share reciprocal development pathways but also are mutually opposite in function. Naïve CD4+ T cells differentiate into distinct functional subsets account to the local cytokine environment. Moreover, under certain inflammatory milieu, differentiated Treg cells can be converted into Th17 cells [13,18]. TGF-β alone induces the differentiation into Treg cells, but in an IL-1- and/or IL-6-rich inflammatory milieu, the Th17 generation is enhanced while the Treg cells are inhibited [18]. The elevated levels of IL-6 found in ARDS patients and non-survivors compared to the control group and survivors, respectively, are in line with the mechanism by which Th17 cells are promoted while Treg cells are suppressed. The Th17/Treg balance toward Th17 cells might enhance the local accumulation of inflammatory mediators, and ultimately create a pathogenic proinflammatory loop to amplify proinflammatory responses in patients with ARDS.

The balance between Th17 and Treg cells has been suggested as a new paradigm for a number of different inflammation and autoimmune diseases [13]. Given the non-synchronous changes in Th17 and Treg cells, we used Th17/Treg to define the relationship between inflammation status and regulatory condition of immune system. Our study demonstrated that in peripheral blood the Th17/Treg ratio increased in ARDS patients compared with the healthy controls. The Th17/Treg ratio was also higher in patients with severe ARDS as compared to those with mild or moderate ARDS. In addition, a highly significant Th17/Treg ratio was found in favor of a proinflammatory Th17-response in non-survivors. Correction of the Th17/Treg imbalance may help maintain the immune system in a steady state, and exhibit a therapeutic benefit for this disease. Indeed, two studies have shown that losartan and alanyl-glutamine may protect mice from lipopolysaccharide-induced lung injury by suppressing Th17 immune responses and modulating the Th17/Treg balance in favor of Treg cells, respectively [5,12].

Although clinical scores, such as the APACHE II [21], SOFA [22] and lung injury score [23] have been widely used in clinical practice to predict outcome in critically ill patients, the early risk-stratification of these patients and their prognosis, as well as accurate monitoring of the effects of clinical treatment, remain a crucial challenge in critical care. Recently, the new Berlin definition has emphasized the notion that ARDS mortality markedly increased with greater severity of hypoxemia as assessed with PaO$_2$/FiO$_2$ [2]. In the present study, negative and moderate correlations were observed between the Th17/Treg ratio and PaO$_2$/FiO$_2$, indicating that the higher the Th17/Treg ratio, the more adverse the outcome in ARDS patients. Interestingly, although APACHE II score, SOFA score, and lung injury score all had significantly positive correlations with the Th17/Treg ratio, the Spearman’s correlation coefficient was the highest between the Th17/Treg ratio and lung injury score, which is more suited to discriminate pulmonary-specific outcomes [23,27]. Meanwhile, we further found that the AUC for Th17/Treg ratio for predicting 28-day mortality in ARDS patients was higher than that for the APACHE II score, SOFA score, lung injury score or PaO$_2$/FiO$_2$. However, the AUC for the lung injury score and PaO$_2$/FiO$_2$ were lower, likely because they are measures of initial lung injury severity and never intended as a prognostic tool in ARDS. Although the Th17/Treg ratio in combination with the APACHE II score slightly increased the AUC for predicting 28-day mortality, there was no difference compared with the Th17/Treg ratio alone. Moreover, the Th17/Treg ratio, APACHE II score, and SOFA score were found to be independent predictors of 28-day mortality in ARDS patients, and those patients with a ratio of Th17/Treg >0.79 had a higher mortality rate. Taken together, our findings strongly suggest that the Th17/Treg ratio is a potential indicator for the degree of lung injury and a good index for evaluation of prognosis in ARDS patients.

Limitations

There were some limitations to this study. First, this is a single-center study and the sample size was not large, thus restricting generalizability. However, our data would be representative enough to observe the alteration of circulating Th17 and Treg cells and the correlation between the Th17/Treg ratio with disease severity and outcome. Moreover, enrolled patients are a mixed population of ARDS, including pulmonary and extrapulmonary ARDS. Further studies with larger numbers of patients are required to confirm our findings. Second, we just investigated the changes in Th17 and Treg cells from peripheral blood. Ideally, samples should be taken either from the alveolar spaces or lung tissue where the inflammatory events are occurring. However, samples obtained through bronchoalveolar lavage and/or biopsies are limited by complexity, especially among critically ill patients in ICU. More importantly, the alteration of circulating Th17 and Treg cells is present in ARDS, and is associated with increased disease severity and risk of mortality, indicating that our method is safe and feasible. Third, the change in functional immunocompetent cells...
was only measured at one time point, because we intended to focus on understanding the effect of the early, inflammatory phase of ARDS on clinical outcome. However, the resolution phase is also important for us to more comprehensively understand the pathophysiological process occurring in ARDS. Therefore, further studies are warranted to longitudinally measure the dynamic changes in the immunological status of patients during the whole time course of ARDS. Finally, this study was not designed to assess the association between the Th17/Treg ratio and the development of ARDS, and this will be the focus of our next study.

Conclusions

In summary, Th17 cells and Treg cells increased in the peripheral blood of patients with early ARDS, and higher Th17 to Treg cell ratio may be associated with poorer prognosis. Moreover, strategies designed to restore the Th17/Treg balance may be a novel and effective therapeutic approach in ARDS.

Key messages

- In patients with early ARDS, the peripheral circulating Th17 and Treg cells and their associated cytokines increased
- The Th17/Treg ratio towards the Th17 cell subset contributes to the pathogenesis of ARDS. The Th17/Treg imbalance may represent a potential therapeutic target and risk indicator in early ARDS.

Abbreviations

ALI: acute lung injury; APACHE II score: acute physiologic and chronic health evaluation II score; ARDS: acute respiratory distress syndrome; AUC: area under the curve; BALF: bronchoalveolar lavage fluid; BMI: body mass index; CRP: C-reactive protein; EDTA: ethylene diamine tetraacetate acid; ELISA: enzyme-linked immunosorbent assay; NK: natural killer; OR: odds ratio; PaO$_2$/FiO$_2$: arterial partial pressure of oxygen/inspired oxygen fraction; PBMC: peripheral blood mononuclear cell; PCT: procalcitonin; PBS: phosphate-buffered saline; ROC: receiver operating characteristics; SOFA score: sequential organ failure assessment score; TGF: transforming growth factor; Th cell: T helper cell; TNF: tumor necrosis factor; Treg cell: regulatory T cell.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Z-C J, J-X Z, and Z-X Y participated in study design, data collection and interpretation, and wrote the study protocol. M-S J, J Y, C C, J L, H F Y, and Y L participated in study design, analyzed data, and performed statistical analysis. Z-C J and Z-X Y drafted the manuscript. All authors read and approved the final manuscript.

Received: 7 August 2014 Accepted: 13 February 2015
Published online: 11 March 2015

References

1. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest. 2012;122:2731–40.
2. Definition Task Force ARDS. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–33.
3. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306:L217–30.
4. Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306:L709–25.
5. Liu J, Zhang PS, Yu Q, Liu L, Yang Y, Guo FM, et al. Losartan inhibits conventional dendritic cell maturation and Th1 and Th17 polarization responses: Novel mechanisms of preventive effects on lipopolysaccharide-induced acute lung injury. Int J Mol Med. 2012;29:269–76.
6. Nakajima T, Suarez CJ, Lin KW, Jen KY, Schnitzer JE, Makani SS, et al. T cell pathways involving CTLA4 contribute to a model of acute lung injury. J Immunol. 2010;184:5835–41.
7. D’Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, et al. CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest. 2009;119:2898–913.
8. Adamzik M, Broll I, Steinnmann J, Westendorf AM, Rehfeld I, Kreissig C, et al. An increased alveolar CD4+CD25+Foxp3+ regulatory T cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality. Intensive Care Med. 2013;39:1743–51.
9. Garibaldi BT, D’Alessio FR, Mock JR, Files DC, Chau E, Eto Y, et al. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment. Am J Respir Cell Mol Biol. 2013;48:35–43.
10. Wang L, Zhao L, Lv J, Yin Q, Liang X, Chu Y, et al. BLT1-dependent alveolar recruitment of CD4(+)(CD25(+)(Foxp3(+) regulatory T cells is important for resolution of acute lung injury. Am J Respir Crit Care Med. 2012;186:989–98.
11. Guo Z, Wen Z, Qin A, Zhou A, Liao Z, Liu Z, et al. Anti-ense oligonucleotide treatment enhances the recovery of acute lung injury through IL-10-secreting M2-like macrophage-induced expansion of CD4+ regulatory T cells. J Immunol. 2013;190:4337–48.
12. Hou YC, Pai MH, Liu JJ, Yeh SL. Alanyl-glutamine resolves lipopolysaccharide-induced lung injury in mice by modulating the polarization of regulatory T cells and Th helper 17 cells. J Nutr Biochem. 2013;24:1555–63.
13. Nacac M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13:668–77.
14. Newcomb DC, Peebles Jr RS. Th17-mediated inflammation in asthma. Curr Opin Immunol. 2013;25:75–60.
15. Kononova TE, Urazova OI, Novitiski W, Churina EG, Kolobovnikova YV, Ignatov MW, et al. Functional activity of Th17 lymphocytes in pulmonary tuberculosis. Bull Exp Biol Med. 2014;157:743–5.
16. Chang SH, Mirabolafathnazad SG, Katta H, Cumpian AM, Gong L, Caetano MS, et al. Th helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA. 2014;111:5664–9.
17. Vargas-Rojas MV, Ignatov MV, et al. Functional activity of Th-17 lymphocytes in pulmonary inflammation. Mediat Inflamm. 2013;2013:571738.
18. Baro R, Enamorado A, Vicente-Nieto D, Colomer A, Bosch A, Tarrin V, et al. T helper cell polarization and regulatory T cell activity in the lung. J Immunol. 2013;191:1422–9.
19. Li C, Yang P, Sun Y, Li T, Wang C, Wang Z, et al. IL-17 response mediates acute lung injury induced by lipopolysaccharide in mice. J Mol Cell Mol Med. 2013;17:2307–20.
20. Halwani R, Al-Muhsen S, Hamid Q. T helper 17 cells in airway diseases: from basic to clinical research. Acta Derm Venereol. 2012;92:451–9.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.
22. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.
23. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138:720–3.
24. Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB. Pathogenic effects of interleukin-17A in induction of Sjögren’s syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther. 2010;12:R220.
25. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 2004;202:145–56.

26. Perl M, Lomas-Neira J, Venet F, Chung CS, Ayala A. Pathogenesis of indirect (secondary) acute lung injury. Expert Rev Respir Med. 2011;5:115–26.

27. Kangelaris KN, Calfee CS, May AK, Zhuo H, Matthay MA, Ware LB. Is there still a role for the lung injury score in the era of the Berlin definition ARDS? Ann Intensive Care. 2014;4:4.